Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, Sieper J
Klinikum Benjamin Franklin, Medizinische Klinik I, Rheumatologie, Hindenburgdamm 30, 12200 Berlin, Germany.
Z Rheumatol. 2003 Jun;62(3):264-73. doi: 10.1007/s00393-003-0522-y.
The purpose of this study was the validation of a German translation of the Bath Ankylosing Spondylitis Index (BASDAI).
The German translation of the BASDAI was validated using data of 134 patients with ankylosing spondylitis (AS) from a spondyloarthropathy cohort. For validation the BASDAI was compared with parameters assessed by physicians (physicians global, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), spinal mobility (BASMI), swollen joints, enthesitis (yes or no)), and parameters assessed by patients themselves (pain, function (BASFI) and quality of life (SF-12)). The discriminative validity was analyzed by comparison of BASDAI scores of patients subgroups who have different levels of disease severity. The sensibility to change was analyzed by using follow-up data of a clinical trial on efficacy of the anti-tumor necrosis factor (TNF) alpha agent infliximab in 70 AS-patients with active and severe disease.
The German translation of the BASDAI was easy to understand, the translation back to English corresponded well with the original English version. The 6 questions of the BASDAI represent different aspects of disease but correlated also well with each other (r < 0.65). There was a good internal consistency for all 6 questions (Cronbach's Alpha 0.82), strong correlations to the physician's global (r = 0.659), pain (r = 789), function (BASFI; r = 0.752) and to CRP and ESR confirming that the BASDAI assesses a comprehensive picture of patient's disease activity. For subgroups of patients with different levels of disease severity or with different manifestations the BASDAI showed good discriminative properties. The BASDAI was sensitive to change during treatment with infliximab (effect size 1.18).
The German translation of the BASDAI is easy to use, reliable, and sensitive to change for the assessment of disease activity in AS.
本研究旨在验证巴斯强直性脊柱炎疾病活动指数（BASDAI）德文版的有效性。
采用来自脊柱关节病队列的134例强直性脊柱炎（AS）患者的数据，对BASDAI德文版进行验证。为进行验证，将BASDAI与医生评估的参数（医生整体评估、C反应蛋白（CRP）、红细胞沉降率（ESR）、脊柱活动度（BASMI）、关节肿胀、附着点炎（是或否））以及患者自身评估的参数（疼痛、功能（BASFI）和生活质量（SF - 12））进行比较。通过比较疾病严重程度不同的患者亚组的BASDAI评分，分析其区分效度。利用一项关于抗肿瘤坏死因子（TNF）α药物英夫利昔单抗对70例活动期和重度AS患者疗效的临床试验的随访数据，分析其对变化的敏感性。
BASDAI德文版易于理解，回译成英文与原始英文版契合度良好。BASDAI的6个问题代表了疾病的不同方面，但彼此之间相关性也很强（r < 0.65）。所有6个问题具有良好的内部一致性（Cronbach's Alpha 0.82），与医生整体评估（r = 0.659）、疼痛（r = 0.789）、功能（BASFI；r = 0.752）以及CRP和ESR有很强的相关性，证实BASDAI评估了患者疾病活动的综合情况。对于疾病严重程度不同或表现不同的患者亚组，BASDAI显示出良好的区分特性。BASDAI在英夫利昔单抗治疗期间对变化敏感（效应大小1.18）。
BASDAI德文版易于使用、可靠，且对评估AS疾病活动的变化敏感。
